EUVIMEDEUVIMED entdecken
Crossref

Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity

Xinzhou Guo iD, Florence T Bourgeois, Tianxi Cai

Statistical Methods in Medical Research · 2024

DOI: 10.1177/09622802241247719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Methods in Medical Research, 2024. Verfasst von Xinzhou Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics, Hong Kong University of Science and Technology, Hong Kong, China. Hauptthemen laut MEDLINE: Biomarkers, Randomized Controlled Trials as Topic, Models, Statistical, Infliximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: FDA HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

When the primary endpoints in randomized clinical trials require long term follow-up or are costly to measure, it is often desirable to assess treatment effects on surrogate instead of clinical endpoints. Prior to adopting a surrogate endpoint for such purposes, the extent of its surrogacy on the primary endpoint must be assessed. There is a rich statistical literature on assessing surrogacy in the overall population, much of which is based on quantifying the proportion of treatment effect on the primary endpoint that is explained by the treatment effect on the surrogate endpoint. However, the surrogacy of an endpoint may vary across different patient subgroups according to baseline demographic characteristics, and limited methods are currently available to assess overall surrogacy in the presence of potential surrogacy heterogeneity. In this paper, we propose methods that incorporate covariates for baseline information, such as age, to improve overall surrogacy assessment. We use flexible semi-non-parametric modeling strategies to adjust for covariate effects and derive a robust estimate for the proportion of treatment effect of the covariate-adjusted surrogate endpoint. Simulation results suggest that the adjusted surrogate endpoint has greater proportion of treatment effect compared to the unadjusted surrogate endpoint. We apply the proposed method to data from a clinical trial of infliximab and assess the adequacy of the surrogate endpoint in the presence of age heterogeneity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersRandomized Controlled Trials as TopicModels, StatisticalInfliximabHumansEndpoint DeterminationTreatment OutcomeStatistics, NonparametricComputer Simulation

Stichwörter der Autor:innen

Covariate-adjustedheterogeneityproportion of treatment effect explainedrandomized clinical trialssurrogacy

Substanzen

BiomarkersInfliximab

Autor:innen und Institutionen

  • Department of Mathematics, Hong Kong University of Science and Technology, Hong Kong, China.
  • Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA, USA.
  • Pediatric Therapeutics and Regulatory Science Initiative, Computational Health Informatics Program (CHIP), Boston Children's Hospital, Boston, MA, USA.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

ORCID-Profile: Xinzhou Guo

Förderung

  • FDA HHS
  • NLM NIH HHS

Zitieren

APA

Guo, X., Bourgeois, F. T., & Cai, T. (2024). Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity. Statistical Methods in Medical Research. https://doi.org/10.1177/09622802241247719

Vancouver

Guo X, Bourgeois FT, Cai T. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity. Statistical Methods in Medical Research. 2024. doi:10.1177/09622802241247719

BibTeX
@article{Guo2024,
  author = {Guo, Xinzhou and Bourgeois, Florence T and Cai, Tianxi},
  title = {Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity},
  journal = {Statistical Methods in Medical Research},
  year = {2024},
  doi = {10.1177/09622802241247719}
}
Kostenlos starten →